Cancer Survivors Program
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMasaryk Memorial Cancer Institute
About this trial
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.
Eligibility criteria
Qualifiers
The patient understands the information provided and agrees to participate in the study.
Age 18 years or older.
Histologically confirmed invasive breast cancer or invasive prostate cancer.
for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated
Disqualifiers
Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)
Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer).
Recurrence of cancer
Metastatic disease
Trial design
Treatments tested in this trial
- active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov